Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecularchaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60,the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotectivebut a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examplesof specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicatea pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response totreatment, as well as for preventing and treating CVD. © 2011 Bentham Science Publishers.
Rizzo, M., Macario, A., de Macario, E.C., Gouni-Berthold, I., Berthold, H.K., Rini, G.B., et al. (2011). Heat Shock Protein-60 and Risk for Cardiovascular Disease. CURRENT PHARMACEUTICAL DESIGN, 17(33), 3662-3668 [10.2174/138161211798220981].
Heat Shock Protein-60 and Risk for Cardiovascular Disease.
RIZZO, Manfredi;ZUMMO, Giovanni;CAPPELLO, Francesco;RINI, Giovam Battista
2011-01-01
Abstract
Cardiovascular disease (CVD) is a leading cause of morbidity and mortality worldwide. There is growing evidence that molecularchaperones, many of which are heat shock proteins HSPs, are involved in CVD pathogenesis. In this review we focus on HSP60,the human mitochondrial chaperone that also displays extramitochondrial and extracellular functions. HSP60 is typically cytoprotectivebut a number of stress conditions determine its conversion to a potentially toxic molecule for cells and tissues. We present illustrative examplesof specific subtypes of CVD where HSP60 is implicated in the initiation and/or progression of disease. The data not only indicatea pathogenic role for HSP60 but also its potential as a biomarker with applications for diagnosis, assessing prognosis and response totreatment, as well as for preventing and treating CVD. © 2011 Bentham Science Publishers.File | Dimensione | Formato | |
---|---|---|---|
99 Curr Pharm Des 2011.pdf
Solo gestori archvio
Dimensione
7.19 MB
Formato
Adobe PDF
|
7.19 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
RW 20. Rizzo et al., CPD 2011.pdf
accesso aperto
Dimensione
404.76 kB
Formato
Adobe PDF
|
404.76 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.